Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

793.26 -14.39 (-1.78%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount ↗

September 09, 2026

Via Chartmill

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

September 08, 2026

Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p...

Via StockStory

Topics Stocks

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

September 02, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron...

Via Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) Surges After Crushing Q2 Estimates with Revenue and EPS Beat ↗

July 30, 2026

Via Chartmill

Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount ↗

July 24, 2026

Via Chartmill

$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

August 24, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron...

Via Benzinga

Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks

August 17, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Via StockStory

Topics Artificial Intelligence

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗

August 14, 2026

They are way more than just GLP-1 stocks.

Via The Motley Fool

Topics Intellectual Property

If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 14, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron...

Via Benzinga

The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call

August 06, 2026

Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s e...

Via StockStory

Topics Earnings

1 Value Stock with Promising Prospects and 2 We Avoid

August 04, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

Via StockStory

Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Revenue surged 17% as Dupixent and EYLEA HD posted record sales.

Via The Motley Fool

Topics Earnings

REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

July 31, 2026

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion....

Via StockStory

Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

Revenue surged 17% as Dupixent and EYLEA HD posted record sales.

Via The Motley Fool

Topics Earnings

Regeneron Pharmaceuticals Q2 Earnings Call Highlights ↗

July 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP...

Via MarketBeat

Topics ETFs Earnings

Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

July 30, 2026

Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billi...

Via StockStory

Topics Artificial Intelligence

Regeneron (REGN) To Report Earnings Tomorrow: Here Is What To Expect

July 28, 2026

Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know. Regeneron beat analysts’ reven...

Via StockStory

Topics Artificial Intelligence

3 Cash-Heavy Stocks with Questionable Fundamentals

July 27, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

All three can be bought on the dip.

Via The Motley Fool

Topics Intellectual Property

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

July 14, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗

July 01, 2026

It might pull it off, provided several things fall right in place.

Via The Motley Fool

Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗

June 29, 2026

Via Chartmill

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Via The Motley Fool

Topics Initial Public Offering

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Via The Motley Fool

This Stock Is Up 58% This Year. Is It too Late to Buy? ↗

June 17, 2026

There could be additional catalysts for this drugmaker over the next year.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

June 17, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.